Nottingham receives go ahead for new £30m life science facility
pharmafile | August 19, 2015 | News story | Manufacturing and Production, Research and Development | BioCity Nottingham, R&D
Hundreds of pharma jobs are expected to be created in Nottingham after the construction of a new £30 million life science building received the go ahead from local council bosses.
The facility, which is expected to be completed in 2017, is a move to bring more life science employers to Nottingham, and create around 250 specialist bioscience jobs, with 700 more created over a 30-year period.
The five-story state-of-the-art facility will be an extension of the city’s BioCity complex, and will be operated by BioCity Group after signing contracts with Nottingham City Council.
Councillor Jon Collins, leader for Nottingham City Council and portfolio holder for Strategic Regeneration, says: “This is a significant development because not only will it cement our position as the UK’s fastest growing life science community, bringing new investment and job opportunities in one of our key growth sectors, but it will also help to regenerate the east side of the city and bring job opportunities during its construction.”
It has also been announced that the drug discovery firm Sygnature Discovery will take up 30,000 square foot premises of the 50,000 square foot available in the new building. This is part of the company’s plan to increase its headcount in Nottingham by a further 70 scientists and support staff, to over 200 by 2018.
The facility will be fitted with high-tech biology and chemistry laboratories which will be built in a range of sizes to allow companies to expand, with ancillary space for commercial leasing to both start-ups and small and medium-sized enterprises.
Operations director at BioCity Toby Reid says: “This is a real statement of intent for Nottingham as a leader in the life sciences sector. Not only have we ensured that a company of the standing of Sygnature Discovery has remained here, as a beacon of excellence in the sector but we’ve also been able to create further space to accommodate our own growth and that of the next generation of innovative entrepreneurs.”
Yasmita Kumar
For the latest job opportunities in the UK pharma industry, go to our new jobs page: www.pharmafile.com/pharmajobs
Related Content
Evotec and Dewpoint Therapeutics enter strategic partnership
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …
BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …
UK industry spend on R&D collaborations grows to £377.3 million
The Association of the British Pharmaceutical Indusxtry (ABPI) has unveiled new data showed that UK …
